Johnson & Johnson has released its financial results for the second quarter of 2025, revealing a 4.1% increase in sales to customers, amounting to $45.636 billion, compared to $43.830 billion in the same period of the previous year. The gross profit stood at $30.651 billion, a slight increase from $30.450 billion, representing a 0.7% rise. The cost of products sold increased by 12.0%, reaching $14.985 billion, up from $13.380 billion. Net earnings per share (diluted) remained stable at $5.53 for the six-month period. The effective tax rate decreased to 17.2% from 17.6% in the previous year. The company experienced a reduction in research and development expenses, which saw a 3.5% decline, totaling $6.741 billion compared to $6.982 billion in the prior period. Additionally, Johnson & Johnson reported a significant net other income of $7.214 billion, contrasting with an expense of $3.057 billion in the previous year. No specific outlook or guidance was provided in the released documents.